Primary Placental Dysfunction Development Features in Women at High Risk and the Prognostic Value of Biochemical Screening

Subject Areas : Journal of Chemical Health Risks

Iryna Marynchyna ¹ , Svitlana Pecheriaha ²

1 - Department of Obstetrics, Gynecology and Perynatology, Bukovinian State Medical University, Chernivtsi, Ukraine
2 - Department of Obstetrics, Gynecology and Perynatology, Bukovinian State Medical University, Chernivtsi, Ukraine

Received: 2021-07-30 Accepted : 2021-11-05 Published : 2021-10-01

Keywords: pregnancy, Hyperandrogenism, Biochemical screening, Placental dysfunction,

Abstract :

Pregnancy forms an integral part of lives of more than half of the female population. During this period, there is greater need to take care of woman's health and the health of her child, so the relevance of this study is conditioned by the necessity of taking a more responsible approach to pregnancy, especially in the early stages. Since the disease detected at an early stage is easier to control and to intervene with minimal threat to the lives of woman and her child in case of threat. As part of the project, 30 pregnant women with hyperandrogenism (HA) and 30 pregnant women with uncomplicated pregnancy were examined. The main selection criterion is the presence of deviations according to the results of the first biochemical screening in pregnant women of the study group and placental dysfunction (PD) according to histological examination. Placental lactogen, estriol, progesterone, fibrin degradation products (FDPs), soluble fibrin monomer complexes (SFMCs) were determined in pregnant women of the “risk group” for the frequency of PD at 16-18 and 20-24 weeks of gestation. Decreased levels of progesterone more than 2 times, placental lactogen 3 times, estriol 1.5 times compared with the data in physiological pregnancy is an indication for a comprehensive examination of pregnant women in the absence of clinical symptoms of PD. Based on this result, it was determined that pregnant women at risk who are prone to abnormalities need to re-tested and examined two to three times more often than other women.

References:

1. Zelinsky A.A., Karaush E.A., 2005. Perinatal Losses and Risk Factors of Obstetric and Gynecological Pathology, Kyiv: Intermed.


2. Milovanov A.P., 1999. Pathology of the Mother – Placenta – Foetus System, Moscow: Meditsina.


3. Sidelnikova V.M., 2011.Preparation and Management of Pregnancy in Women with Recurrent Miscarriage, Moscow: MEDpress-Inform.


4. Strizhakov A.N. Ignatko I.V., 2007. Loss of Pregnancy, Moscow: Medical Information Agency.


5. Azziz R., Nestler J.E., Dewailly D., 2006. Androgen Excess Disorders in Women: Polycystic Ovari Syndrome and Other Disorders, Totowa: Humana Press.


6. Beer A.E., Kwak J., 2000. Reproductive medicine program. Chicago Medical School. 11, 201-240.


7. Cuckle H.S., 2010. Monitoring quality control of nuchal translucency. Clinics in Laboratory Medicine. 30, 593-604.


8. Strukov A.I., Serov V.V., 2010. Pathological Anatomy, Moscow: Litterra.


9. Ailamazyan E.K. Obstetrics., 2005. Gynaecology, Moscow: SpetsLit.


10. Bodyazhina V.I., Zhmakin K.N., Kiryushchenkov A.P., 1986.Obstetrics, Moscow: Meditsina.


11. Mikhailenko E.T., 1982. Physiological Obstetrics, Kyiv: Vyshcha shkola.


12. Serov V.N., Strizhakov A.N., Markin S.A., 1989. Practical Obstetrics. A Guide for Doctors, Moscow: Meditsina.


13. Gavrilova L.V., 2000. On postcoital contraception. Family Planning Magazine. 1, 45-53.


14. Saidova R.A., 2000. Modern contraceptives. Family Planning Magazine. 2, 89-94.


15. Politaev G.F., 2000. Contraception: Options of choice. Family Doctor. 18, 111-117.


16. Savelyeva I.S., 1999. Influence hormonal contraceptives for the risk of developing breast cancer. Gynaecology. 1, 2-7.


17. Ketting E., Visser A.P., 1996. Contraception in the Netherlands: Low abortion rate. Family Planning Magazine. 4, 67-81.


18. Amin S.B., Sinkin R.A., Glantz J.C., 2007. Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes. American Journal of Obstetrics & Gynaecology. 197, 486.


19. Mittendorf R., Dambrosia J., Pryde P.G., 2002. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics & Gynaecology. 186, 1111


20. Stika C.S., Gross G.A., Leguizamon G., 2002. A prospective randomised safety trial of celecoxib for treatment of preterm labour. American Journal of Obstetrics & Gynaecology. 187, article number 653.


21. Goldenberg R.L., 2002. The management of preterm labour. American Journal of Obstetrics & Gynaecology. 100, 1020.


22. Simhan H.N., Caritis S.N., 2007. Prevention of preterm delivery. The New England Journal of Medicine. 13, 75-81.